HPV 16 and its role in the development of cervical cancer: prevention, diagnosis and treatment
DOI:
https://doi.org/10.56782/pps.381Keywords:
HPV 16, cervical cancer, cytology, vaccineAbstract
Human papillomavirus type 16 (HPV 16) is the most oncogenic and one of the most common genotypes of human papillomavirus. Its oncogenic properties make it play a key role in the development of many cancers, including cervical, throat, anal and other malignant tumors. The main route of HPV infection is sexual contact. This article characterizes the HPV 16 virus and its unique oncogenic Human papillomavirus type 16 (HPV 16) is the most oncogenic and one of the most common genotypes of human papillomavirus. Its oncogenic properties make it play a key role in the development of many cancers, including cervical, throat, anal and other malignant tumors. The main route of HPV infection is sexual contact. This article characterizes the HPV 16 virus and its unique oncogenic properties. The epidemiology of infections and preventive strategies, including vaccinations and screening programs, which have significantly reduced the number of cases of HPV-related cancers, are discussed. Modern diagnostic methods, such as genetic tests and cytology, which enable early detection of infections and precancerous lesions, are also presented. The article also addresses the issues of treatment of lesions caused by HPV 16, including local therapies used in the case of precancerous lesions and comprehensive methods of treating advanced cancers. The last part discusses research perspectives, such as the development of new vaccines and immunotherapy, which may play a key role in the fight against this virus in the future. This article highlights the importance of an interdisciplinary approach to the prevention, diagnosis, and treatment of HPV 16 infections, which is essential to reducing the global burden of cancers associated with this virus.
Downloads
References
1. Yousefi, Z.; Aria, H.; Ghaedrahmati, F.; et al. An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. Front. Immunol. 2022, 12, Art. No: 805695. DOI: 10.3389/fimmu.2021.805695 DOI: https://doi.org/10.3389/fimmu.2021.805695
2. Nelson, C.W.; Mirabello, L. Human papillomavirus genomics: Understanding carcinogenicity. Tumour Virus Res. 2023, 15, Art. No: 200258. DOI: 10.1016/j.tvr.2023.200258 DOI: https://doi.org/10.1016/j.tvr.2023.200258
3. Demarco, M.; Hyun, N.; Carter-Pokras, O.; et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. eClinicalMedicine 2020, 22, Art. No: 100293. DOI: 10.1016/j.eclinm.2020.100293 DOI: https://doi.org/10.1016/j.eclinm.2020.100293
4. Baedyananda, F.; Sasivimolrattana, T.; Chaiwongkot, A.; et al. Role of HPV16 E1 in cervical carcinogenesis. Front. Cell Infect. Microbiol. 2022, 12, Art. No: 955847. DOI: 10.3389/fcimb.2022.955847 DOI: https://doi.org/10.3389/fcimb.2022.955847
5. Yu, L.; Majerciak, V.; Zheng, Z.M. HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation. Int. J. Mol. Sci. 2022, 23, Art. No: 4943. DOI: 10.3390/ijms23094943 DOI: https://doi.org/10.3390/ijms23094943
6. Muñoz, N.; Bosch, F.X.; de Sanjosé, S.; et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348, 518–527. DOI: 10.1056/NEJMoa021641 DOI: https://doi.org/10.1056/NEJMoa021641
7. Mikuličić, S.; Strunk, J.; Florin, L. HPV16 Entry into Epithelial Cells: Running a Gauntlet. Viruses 2021, 13, Art. No: 2460. DOI: 10.3390/v13122460 DOI: https://doi.org/10.3390/v13122460
8. Moody, C.A. Mechanisms by which HPV Induces a Replication Competent Environment in Differentiating Keratinocytes. Viruses 2017, 9(9), Art. No: 261. DOI: 10.3390/v9090261 DOI: https://doi.org/10.3390/v9090261
9. Shaikh, F.; Sanehi, P.; Rawal, R. Molecular screening of compounds to the predicted Protein-Protein Interaction site of Rb1-E7 with p53- E6 in HPV. Bioinformation 2012, 8, 607-612. DOI: 10.6026/97320630008607 DOI: https://doi.org/10.6026/97320630008607
10. Broniarczyk, J.; Koczorowska, M. M.; Durzyńska, J.; Warowicka, A.; Goździcka-Józefiak, A. Struktura i właściwości wirusa brodawczaka ludzkiego [Structure and properties of human papillomavirus]. Biotechnologia 2010, 90, 126-145. DOI: 10.18388/biotech.2010.90.126
11. Piesiaków, M. L.; Imko-Walczuk, B.; Osiecka, B.; Sławińska, D.; Sławiński, M. Wirusy onkogenne w etiopatogenezie nowotworów skóry u chorych po przeszczepieniach narządów. [Carcinogenic viruses in etiopathogenesis of skin cancers in patients after organ transplantation.] Postępy Hig. Med. Dosw. 2016, 70, 1256-1265. DOI: 10.5604/17322693.1226494 DOI: https://doi.org/10.5604/17322693.1194807
12. Warowicka, A.; Nawrot, R.; Broniarczyk, J.; Węglewska, M.; Goździcka-Józefiak, A. Wirusy onkogenne a nowotwory. [Oncogenic viruses and cancer]. Postępy Biochemii 2020, 66, 385-394. DOI: 10.18388/pb.2020_360 DOI: https://doi.org/10.18388/pb.2020_360
13. Rafael,T. S.; Rotman, J.; Brouwer, O. R.; Poel, H. G.; Mom, C. H.; Kenter, G. G.; Gruijl, T. D.;Jordanova, E. S. Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis. J. Clin. Med. 2022, 11, Art. No: 1101; DOI: 10.3390/jcm11041101 DOI: https://doi.org/10.3390/jcm11041101
14. Zhou, C.; Toung, Z. K.; Frazer, I. H. Papillomavirus Immune Evasion Strategies Target the Infected Cell. Front. Immunol. 2019, 9, Art. No: 682. DOI: 10.3389/fonc.2019.00682 DOI: https://doi.org/10.3389/fonc.2019.00682
15. Senba, M.; Mori, N. Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection. Oncol. Rev. 2012, 6(2), Art. No: e17. DOI: 10.4081/oncol.2012.e17 DOI: https://doi.org/10.4081/oncol.2012.e17
16. Williamson, A.L. Recent Developments in Human Papillomavirus (HPV) Vaccinology. Viruses 2023, 15, Art. No: 1440. DOI: 10.3390/v15071440 DOI: https://doi.org/10.3390/v15071440
17. Zou, K.; Huang, Y.; Li, Z. Prevention and treatment of human papillomavirus in men benefits both men and women. Front. Cell. Infect. Microbiol. 2022, 12, Art. No: 1077651. DOI: 10.3389/fcimb.2022.1077651 DOI: https://doi.org/10.3389/fcimb.2022.1077651
18. Kechagias, K.S.; Kalliala, I.; Bowden, S.J.; et al. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis. BMJ 2022, 378, Art. No: e070135. DOI: 10.1136/bmj-2022-070135 DOI: https://doi.org/10.1136/bmj-2022-070135
19. Eriksen, D.O.; Jensen, P.T.; Schroll, J.B.; Hammer, A. Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: A systematic review and meta‐analysis. Acta. Obstet. Gynecol. Scand. 2022, 101, 597–607. DOI: 10.1111/aogs.14359 DOI: https://doi.org/10.1111/aogs.14359
20. Malagon, T.; MacCosham, A.; Burchell, A.N.; El-Zein, M.; et al. Proportion of Incident Genital Human Papillomavirus Detections not Attributable to Transmission and Potentially Attributable to Latent Infections: Implications for Cervical Cancer Screening. Clin. Infect. Dis. 2021, 75, 365–371. DOI: 10.1093/cid/ciab985 DOI: https://doi.org/10.1101/2021.05.12.21256547
21. Lin, R.; Jin, H.; Fu, X. Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis. Expert. Rev. Vaccines 2023, 22, 1168-1178. DOI: 10.1080/14760584.2023.2287135 DOI: https://doi.org/10.1080/14760584.2023.2287135
22. Human Papillomavirus Vaccines WHO: WHO Position. Wkly. Epidemiol. Rec. 2022, 97, 645–672.
23. Brisson, M.; Bénard, É.; Drolet, M.; Bogaards, J.A.; Baussano, I.; et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health 2016, 1, 8–17. DOI: 10.1016/S2468-2667(16)30001-9 DOI: https://doi.org/10.1016/S2468-2667(16)30001-9
24. Gultekin, M.; Ramirez, P.T.; Broutet, N.; Hutubessy, R. World Health Organization call for action to eliminate cervical cancer globally. Int. J. Gynecol. Cancer 2020, 30, 426–427. DOI: 10.1136/ijgc-2020-001285 DOI: https://doi.org/10.1136/ijgc-2020-001285
25. Glinska, P.; Komerska, K.; Janik,B.; et al. HPV testing in Polish population-based cervical cancer screening programme (HIPPO project)—study protocol of a randomised healthcare policy trial. BMC Cancer 2023, 23, Art. No: 1118. DOI: 10.1186/s12885-023-11597-5 DOI: https://doi.org/10.1186/s12885-023-11597-5
26. Open Research. Available online: https://openbadania.pl/educations/article/bezpieczny-seks-i-profilaktyka-raka-szyjki-macicy (accessed 10.01.2025)
27. Repp, K.K.; Nielson, C.M.; Fu, R.; et al. Male Human Papillomavirus Prevalence and Association With Condom Use in Brazil, Mexico, and the United States. J. Infect. Dis. 2012, 205, 1287–1293. DOI: 10.1093/infdis/jis181 DOI: https://doi.org/10.1093/infdis/jis181
28. Chih, H.J.; Lee, A.H.; Colville, L.; et al. A review of dietary prevention of human papillomavirus-related infection of the cervix and cervical intraepithelial neoplasia. Nutr. Cancer 2013, 65, 317-28. DOI: 10.1080/01635581.2013.757630 DOI: https://doi.org/10.1080/01635581.2013.757630
29. Irish, L.A.; Kline, C.E.; Gunn, H.E.; et al. The role of sleep hygiene in promoting public health: A review of empirical evidence. Sleep. Med. Rev. 2015, 22, 23-36. DOI: 10.1016/j.smrv.2014.10.001 DOI: https://doi.org/10.1016/j.smrv.2014.10.001
30. Coker, A.L.; Bond, S.; Madeleine, M.M.; Luchok, K.; Pirisi, L. Psychosocial stress and cervical neoplasia risk. Psychosom. Med. 2003, 65, 644-651. DOI: 10.1097/01.psy.0000041471.57895.08 DOI: https://doi.org/10.1097/01.PSY.0000041471.57895.08
31. Batman, A.M.; Miles, M.F. Translating Alcohol Research Opportunities and Challenges. Alcohol Res. Curr. Rev. 2015, 37, 7-14. DOI: 10.35946/arcr.v37.2.01 DOI: https://doi.org/10.35946/arcr.v37.1.01
32. Schabath, M.B.; Villa, L.L.; Lin, H.Y.; et al. A prospective analysis of smoking and human papillomavirus (HPV) infection among men in The HPV in Men (HIM) Study. Int. J. Cancer 2013, 134, 2448–2457. DOI: 10.1002/ijc.28567 DOI: https://doi.org/10.1002/ijc.28567
33. Practical Medicine. Available online: https://www.mp.pl/pacjent/ginekologia/badania-i-zabiegi/292320,cytologia-badanie-cytologiczne-wszystko-co-musisz-wiedziec? (accessed 14.01.2025)
34. Walboomers, J.M.; Jacobs, M.V.; Manos, M.M.; et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189, 12-19. DOI: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F DOI: https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
35. World Health Organization. Available online: https://www.who.int/europe/news-room/11-09-2021-who-recommends-dna-testing-as-a-first-choice-screening-method-for-cervical-cancer-prevention? (accessed 16.01.2025)
36. Ronco, G.; Giorgi-Rossi, P.; Carozzi, F.; et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010, 11, pp: 249-257. DOI: 10.1016/S1470-2045(09)70360-2 DOI: https://doi.org/10.1016/S1470-2045(09)70360-2
37. Zheng, Z.; Yang, X.; Yao, X.; Li, L. Prognostic value of HPV 16/18 genotyping and geminin mRNA quantification in low-grade cervical squamous intraepithelial lesion. Bioengineered 2021, 12, 11482-11489. DOI: 10.1080/21655979.2021.2009959 DOI: https://doi.org/10.1080/21655979.2021.2009959
38. Stoler, M.H.; Wright Jr, T.C.; Parvu, V.; Yanson, K.; et al. HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology. Am. J. Clin. Pathol. 2019, 151, 433-442. DOI: 10.1093/ajcp/aqy169 DOI: https://doi.org/10.1093/ajcp/aqy169
39. Torres-Ibarra, L.; Cuzick, J.; Lorincz, A.; Spiegelman, D.; et al. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus–Based Screening in Mexico. JAMA Netw. Open. 2019, 2, Art. No: e1915781. DOI: 10.1001/jamanetworkopen.2019.15781 DOI: https://doi.org/10.1001/jamanetworkopen.2019.15781
40. Singh, M.; Mockler, D.; Akalin, A.; et al. Immunocytochemical colocalization of P16(INK4a) and Ki-67 predicts CIN2/3 and AIS/adenocarcinoma. Cancer Cytopathol. 2012, 120, 26-34. DOI: 10.1002/cncy.20188 DOI: https://doi.org/10.1002/cncy.20188
41. Wentzensen, N.; Schwartz, L.; Zuna, R.E.; et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin. Cancer Res. 2012, 18, 4154-4162. DOI: 10.1158/1078-0432.CCR-12-0270 DOI: https://doi.org/10.1158/1078-0432.CCR-12-0270
42. Bergeron, C.; Ronco, G.; Reuschenbach, M.; et al. The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments. Int. J. Cancer 2015, 136, 2741-2751. DOI: 10.1002/ijc.28900 DOI: https://doi.org/10.1002/ijc.28900
43. Bruno, M.T.; Guaita, A.; Boemi, S.; et al. Performance of p16/Ki67 Immunostaining for Triage of Elderly Women with Atypical Squamous Cells of Undetermined Significance. J. Clin. Med. 2023, 12, Art. No: 3400. DOI: 10.3390/jcm12103400 DOI: https://doi.org/10.3390/jcm12103400
44. McMenamin, M.; McKenna, M.; et al. Clinical Utility of CINtec PLUS Triage in Equivocal Cervical Cytology and Human Papillomavirus Primary Screening. Am. J. Clin. Pathol. 2018, 150, 512-521. DOI: 10.1093/ajcp/aqy073 DOI: https://doi.org/10.1093/ajcp/aqy073
45. Practical Medicine. Available online: https://www.mp.pl/pacjent/badania_zabiegi/263494,kolposkopia (accessed 15.01.2025)
46. Cervix. Available online: https://kolposkopia.com/ kolposkopia/ (accessed 20.01.2025)
47. Wikipedia. The free encyclopedia. Available online: https://pl.wikipedia.org/wiki/Pr%C3%B3ba_Schillera (accessed 20.01.2025)
48. Service of the Republic of Poland. Available online: https://www.gov.pl/web/zdrowie/program-profilaktyki-raka-szyjki-macicy-cytologia- (accessed 16.01.2025)
49. Service of the Republic of Poland. Available online: https://www.gov.pl/web/zdrowie/dwa-nowoczesne-badania-w-profilaktyce-raka-szyjki-macicy (accessed 16.01.2025)
50. Jach, R.; Mazurec, M.; Trzeszcz, M.; Stukan, M.; et al. Position on the Scheme of Procedure for Basic Cervical Cancer Screening of the Polish Society of Gynecologists and Obstetricians (PTGiP) – June 2022. Position of the Polish Society of Colposcopy and Cervical Pathophysiology – August 2022. [Stanowisko dotyczące schematu postępowania w skriningu podstawowym raka szyjki macicy Polskiego Towarzystwa Ginekologów i Położników (PTGiP) – czerwiec 2022 roku. Stanowisko Polskiego Towarzystwa Kolposkopii i Patofizjologii Szyjki Macicy – sierpień 2022 roku.] Medycyna Praktyczna – Ginekologia i Położnictwo [Practical Medicine – Gynecology and Obstetrics] 2022, 69-82.
51. Kornovski, Y.; Slavchev, S.; Kostov, S.; et al. Precancerous lesions of the cervix — aetiology, classification, diagnosis, prevention. Oncol. Clin. Pract. 2021, 17(6), 271-276. DOI: 10.5603/OCP.2021.0027 DOI: https://doi.org/10.5603/OCP.2021.0027
52. Tai, Y. J.; Chen, Y. Y.; Hsu, H. C.; Chiang, C. J.; You, S.L.; Chen, H. C.; Chen, C.A.; Cheng, W. F. Clinical management and risk reduction in women with low-grade squamous intraepithelial lesion cytology: A population-based cohort study. PLoS One 2017, 12(12), Art. No: e0188203. DOI: 10.1371/journal.pone.0188203 DOI: https://doi.org/10.1371/journal.pone.0188203
53. Scheungraber, C.; Kleekamp, N.; Schneider, A. Management of low-grade squamous intraepithelial lesions of the uterine cervix. Br. J. Cancer 2004, 90, 975–978. DOI: 10.1038/sj.bjc.6601415 DOI: https://doi.org/10.1038/sj.bjc.6601415
54. Pisarska-Krawczyk, M.; Radomski, D.; Jarząbek-Bielecka, G.; Mizgier, M.; Kędzia, W. Cryotherapy and other ablation techniques in the treatment of cervical intraepithelial neoplasia. [Krioterapia a inne metody ablacyjne w leczeniu śródnabłonkowej neoplazji szyjki macicy]. Curr. Gynecol. Oncol. 2015, 13, 165–171. DOI: 10.15557/CGO.2015.0018 DOI: https://doi.org/10.15557/CGO.2015.0018
55. Center for Preventive Medicine. Mental health. Cervical cryotherapy. Available online: https://cmp.krakow.pl/prywatna/uslugi/poradnia-ginekologiczno-poloznicza/krioterapia-szyjki-macicy/ (accessed on 29 January 2025)
56. World Health Organization. WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. Available online: https://www.who.int/ publications/i/ item/9789241550598 (accessed on 29 January 2025)
57. de Fouw, M.; Oosting, R. M.; Rutgrink, A.; Dekkers, O. M.; Peters, A. A. W.; Beltman, J. A systematic review and meta-analysis of thermal coagulation compared with cryotherapy to treat precancerous cervical lesions in low- and middle-income countries. Int. J. Gynaecol. Obstet. 2019, 147, 14-18. DOI: https://doi.org/10.1002/ijgo.12904
58. Oncogin Gynecology. Surgical fractional laser. Available online: http://onkogin.pl/laser-frakcyjny-chirurgiczny/ (accessed on 29 January 2025)
59. La Guèl Clinic & SPA. LEEP – elektrokonizacja szyjki macicy w przypadku zmian HSIL. Available online: https://www.laguel.pl/leep-elektrokonizacja-szyjki-macicy-w-przypadku-zmian-hsil/ (accessed on 29 January 2025)
60. Martin-Hirsch, P. P. L.; Paraskevaidis, E.; Bryant, A.; Dickinson, H. O.; Keep, S. L. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst. Rev. 2010, 6, Art. No: CD001318. DOI: 10.1002/14651858.CD001318.pub2 DOI: https://doi.org/10.1002/14651858.CD001318.pub2
61. Li, X.; Liu, M.; Ji, Y.; Qu, P. The effectiveness of cold-knife conization (CKC) for post-menopausal women with cervical high-grade squamous intraepithelial lesion: a retrospective study. BMC Surg. 2021, 21, Art. No: 241. DOI: 10.1186/s12893-021-01238-8 DOI: https://doi.org/10.1186/s12893-021-01238-8
62. StatPearls. Publishing. Cold Knife Conization of the Cervix. Available online: https://www.ncbi.nlm. nih.gov/ books/NBK441845/ (accessed on 29 January 2025)
63. Burmeister, C. A.; Khan, S. F.; Schäfer, G.; Mbatani, N.; Adams, T.; Moodley, J.; Prince, S. Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Res. 2022, 13, Art. No: 200238. DOI: 10.1016/j.tvr.2022.200238 DOI: https://doi.org/10.1016/j.tvr.2022.200238
64. National Library of Medicine. Cervical Cancer Treatment. Available online: https://www.ncbi.nlm. nih.gov/books/NBK65985/ (accessed on 30 January 2025)
65. Tewari, K. S.; Sill, M. W.; Penson, R. T.; Huang, H.; Ramondetta, L. M.; Landrum, L. M.; Oaknin, A.; Reid, T. J.; Leitao, M. M.; Michael, H. E.; DiSaia, P. J.; Copeland, L. J.; Creasman, W. T.; Stehman, F. B.; Brady, M. F.; Burger, R. A.; Thigpen, J. T.; Birrer, M. J.; Waggoner, S. E.; Moore, D. H.; Look, K. Y.; Koh, W. J.; Monk, B. J. Final Overall Survival of the Phase III Randomised Trial of Chemotherapy with and without Bevacizumab for Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Lancet 2017, 390, 1654–1663. DOI: 10.1016/S0140-6736(17)31607-0 DOI: https://doi.org/10.1016/S0140-6736(17)31607-0
66. Nowak-Markwitz, E.; Basta, A.; Kotarski, J.; Markowska, J.; Oszukowski, P.; Sajdak, S.; Sawicki, W.; Spaczyński, M. Systemic therapy of recurrent or persistent cancer of the cervix. Recommendations of the Polish Gynecological Society [Rekomendacje Polskiego Towarzystwa Ginekologicznego. Leczenie systemowe nawrotowego i przetrwałego raka szyjki macicy]. Ginekol. Pol. 2015, 86, 712-714. DOI: 10.17772/gp/59225. DOI: https://doi.org/10.17772/gp/59225
67. Massobrio, R.; Bianco, L.; Campigotto, B.; Attianese D.; Maisto, E.; Pascotto, M.; Redda, M. G. R.; Ferrero, A. New Frontiers in Locally Advanced Cervical Cancer Treatment. J. Clin. Med. 2024, 13(15), Art. No: 4458. DOI: 10.3390/jcm13154458 DOI: https://doi.org/10.3390/jcm13154458
68. Mo, Y.; Ma, J.; Zhang, H.; Shen, J.; Chen, J.; Hong, J.; Xu, Y.; Qian, C. Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives. Front. Cell Infect. Microbiol. 2022, 12, Art. No: 909223. DOI: 10.3389/fcimb.2022.909223 DOI: https://doi.org/10.3389/fcimb.2022.909223
69. Rumfield, C. S.; Roller, N.; Pellom, S. T.; Jeffrey, S.; Jochems, C. Therapeutic Vaccines for HPV-Associated Malignancies. Immunotargets Ther. 2020, 9, 167–200. DOI: 10.2147/ITT.S273327 DOI: https://doi.org/10.2147/ITT.S273327
70. Trimble, C. L.; Morrow, M. P.; Kraynyak, K. A.; Shen, X.; Dallas, M. et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 2015, 386, 2078–2088. DOI: 10.1016/S0140-6736(15)00239-1 DOI: https://doi.org/10.1016/S0140-6736(15)00239-1
71. Teffera, Z.; Yihunie, W.; Tegegne, B.; Misganaw, B.; Abebaw, D.; Belayineh, M.; Akelew, Y.; Dilnesa, T.; Adugna, A.; Silabat, B.; Tefera, S.; Belew, H.; Bimrew, L. Efficacy of a novel high risk HPV 16/18 therapeutic vaccine in treating cervical intraepithelial neoplasia and cervical cancer in a clinical trial: A systematic review and meta analysis. World Acad. Sci. J. 2024, 6, Art. No: 52. DOI: 10.3892/wasj.2024.267 DOI: https://doi.org/10.3892/wasj.2024.267
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Katarzyna Łysiak, Anna Łysiak
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
